Hepatology: A New Way to Treat Chronic Choleitis

2020 dated 16 years5 hearing / Biovalley BIOON / --- primary sclerosing cholangitis (PSC) is a rare chronic disease cholangitis, difficult to treatStudyRecently, Professor MichaelTrauner from the Medical University of Vienna Department of Gastroenterology and Hepatology persons showed benefit with respect to treatment of the disease by administering a bile acid synthesis and bile acid receptor agonistThese treatments have been studied in phase III clinical trials, but there is no approvalTo better understand the disease mechanisms of PSC, Trauner led the research team studied MAGL (a participatory lipid metabolism enzymes) mechanism of actionThe study found that in animal models lacking or no pharmacological inhibition, there is better protection of the bile duct disease in an animalThe study has been published in the prestigious "Hepatology" magazinea (Source: Www.pixabay.com)PSC poor prognosis is a rare disease that can lead to cirrhosis of the liver or bile duct cancerIt affects 0.01% of the population, although rare, PSC accounts for more than 10% of all liver transplants, making it Europe's third-largest liver transplant indicationsAlthough the latest study, led MichaelTrauner demonstrated synthesis of bile acids (norUDCA) and bile acid receptor agonist (cilofexor) initial positive role, but there is no drug treatment method PSC approvalIn the present study, in order to better understand the mechanism of PSC, we focus on the research team monoacylglycerol lipase (MAGL) mechanism of actionenzyme plays a key role in the decomposition of fat, but little is known about their behavior in the liver diseasesTrauner assumption that fatty acid metabolism in the biliary epithelium (innermost biliary cells) may be larger role than previously thoughtIn this process, a single MAGL fats into fatty acids, if uncontrolled release, it may cause cell damage and inflammationSo far, researchers have been working on the relationship between the enzyme activity and disease So far, however, it is its role in bile duct disease is still poorly understood Problem authors originally proposed that the degree of inhibition of whether MAGL enzyme can reduce liver injury In the mouse model, or a lack of activity is MAGL induce the occurrence of diseases in the case of drugs that inhibit The results showed no activity in mice seem MAGL significantly reduced symptoms, liver fibrosis (accumulation of connective tissue) and decreased inflammation A further positive effect is observed of its intestinal microbial groups and adjusting the anti-inflammatory effect normalization In about 70% of the cases, PSC and related chronic inflammatory bowel disease, and anti-inflammatory effect in the gut is also beneficial to the liver, so this discovery is also very important Ultimately, the results showed that the inhibition by targeting MAGL is a possible metabolic immune therapy a (Biovalley Bioon.com) Information Source: Apromisingtreatmentforchronicinflammatoryliverdisease Original source: TardelliM, etal (2020) MonoacylglycerolLipaseInhibitionProtectsfromLiverInjuryinMouseModelsofSclerosingCholangitis > Hepatology .doi.org / 10.1002 / hep.30929